Christina Bennett, MS

The VOLFI trial enrolled 105 patients with RAS wild-type metastatic colorectal cancer.

A combination of trifluridine and tipiracil showed some gains in overall survival for patients with metastatic gastric cancer or gastroesophageal junction cancer.

Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease.

BRAF and MEK inhibitors appear to have clinical activity in patients with metastatic melanoma with rare BRAF mutations.

A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.

A study showed patients seem to lack an understanding of the meaning of progression-free survival.

The study found patients with lung cancer referred to palliative care earlier lived longer.

The results of the TAILORx trial went against previous ideas that breast cancer patients with a high Oncotype score who needed chemotherapy and endocrine therapy wouldn't fare well.

Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer.

Maintenance therapy with niraparib may improve survival in patients with ovarian cancer.

A new study found men with breast cancer have higher mortality compared with women, possibly due to lack of awareness.

Researchers examined how metformin and TKI therapy did in combatting lung cancer.

New trial results examine whether there's a drug superior to sorafenib when it comes to treating kidney cancer.

Whether a cancer survivor had a health savings account (HSA) as part of their high-deductible health plan was linked to access to care.

There's been much research done on how cancer of the reproductive organs affects patients' sexuality; this new study included patients with cancers outside the reproductive organs.

A new study shows patients with advanced non­­­­–small-cell lung cancer have preferences on which chemotherapy side effects they'd prefer to avoid which highlights the importance of incorporating patient preferences into treatment.

Study researchers polled 607 women who'd been previously diagnosed with breast cancer to see how recovery time, surgical complications, and cost factored into their decision to receive surgery during treatment.

A new combo may benefit patients with HER-2 positive metastatic breast cancer, according to a new study.

While ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients.

A total of 30 patients were enrolled in an expansion cohort for relapsed/refractory primary mediastinal B-cell lymphoma and received nivolumab and brentuximab vedotin.

A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.

Researchers followed up 10 years after the CALGB 49907 trial to see which treatment led to longer recurrence-free survival.

Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations.

Researchers looked at the time between receiving a diagnosis and beginning chemotherapy to see if a delay in treatment impacted the overall survival in  patients with breast cancer.

The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax.

A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.

Negative trial findings suggest immune checkpoint inhibitors may not be the best type of immunotherapy to treat pancreatic cancer.

The new recommendations will help standardize neoadjuvant clinical trial methodology and develop a path for regulatory review and approval of neoadjuvant therapies in melanoma.

This new study looked at chronic pain rates among cancer survivors, including which survivors report the highest prevalence of pain.